scholarly journals Dephosphorylation of the NPR2 guanylyl cyclase contributes to inhibition of bone growth by fibroblast growth factor

eLife ◽  
2017 ◽  
Vol 6 ◽  
Author(s):  
Leia C Shuhaibar ◽  
Jerid W Robinson ◽  
Giulia Vigone ◽  
Ninna P Shuhaibar ◽  
Jeremy R Egbert ◽  
...  

Activating mutations in fibroblast growth factor (FGF) receptor 3 and inactivating mutations in the NPR2 guanylyl cyclase both cause severe short stature, but how these two signaling systems interact to regulate bone growth is poorly understood. Here, we show that bone elongation is increased when NPR2 cannot be dephosphorylated and thus produces more cyclic GMP. By developing an in vivo imaging system to measure cyclic GMP production in intact tibia, we show that FGF-induced dephosphorylation of NPR2 decreases its guanylyl cyclase activity in growth plate chondrocytes in living bone. The dephosphorylation requires a PPP-family phosphatase. Thus FGF signaling lowers cyclic GMP production in the growth plate, which counteracts bone elongation. These results define a new component of the signaling network by which activating mutations in the FGF receptor inhibit bone growth.

2017 ◽  
Author(s):  
Leia C. Shuhaibar ◽  
Jerid W. Robinson ◽  
Ninna P. Shuhaibar ◽  
Jeremy R. Egbert ◽  
Giulia Vigone ◽  
...  

AbstractActivating mutations in fibroblast growth factor (FGF) receptor 3 and inactivating mutations in the NPR2 guanylyl cyclase cause similar forms of dwarfism, but how these two signaling systems interact to regulate bone growth is poorly understood. Here, by use of a mouse model in which NPR2 cannot be dephosphorylated, we show that bone elongation is opposed when NPR2 is dephosphorylated and thus produces less cyclic GMP. By developing an in vivo imaging system to measure cyclic GMP levels in intact tibia, we show that FGF-induced dephosphorylation of NPR2 decreases its guanylyl cyclase activity in growth plate chondrocytes in living bone. Thus FGF signaling lowers cyclic GMP in the growth plate, which counteracts bone elongation. These results define a new component of the signaling network by which activating mutations in the FGF receptor inhibit bone growth.


2017 ◽  
Author(s):  
Leia C Shuhaibar ◽  
Jerid W Robinson ◽  
Giulia Vigone ◽  
Ninna P Shuhaibar ◽  
Jeremy R Egbert ◽  
...  

Blood ◽  
2004 ◽  
Vol 103 (9) ◽  
pp. 3521-3528 ◽  
Author(s):  
Suzanne Trudel ◽  
Scott Ely ◽  
Yildiz Farooqi ◽  
Maurizio Affer ◽  
Davide F. Robbiani ◽  
...  

Abstract We have previously shown that dysregulation of fibroblast growth factor receptor 3 (FGFR3) by the t(4;14) translocation is a primary event in multiple myeloma (MM) and that activating mutations of FGFR3 are acquired in some cases. We describe here inhibition of wild-type (WT) and constitutively activated mutant FGFR3 autophosphorylation by the small molecule inhibitor, PD173074. Inhibition of FGFR3 in human myeloma cell lines was associated with decreased viability and tumor cell growth arrest. Further, morphologic, phenotypic, and functional changes typical of plasma cell (PC) differentiation, including increase in light-chain secretion and expression of CD31, were observed and this was followed by apoptosis. Finally, using a mouse model of FGFR3 myeloma, we demonstrate a delay in tumor progression and prolonged survival of mice treated with PD173074. These results indicate that inhibition of FGFR3, even in advanced disease associated with multiple genetic changes, may allow the cell to complete its developmental program and render it sensitive to apoptotic signals. In addition, this represents the validation of a therapeutic target in MM that may benefit patients who have a very poor prognosis with currently available treatments. (Blood. 2004;103:3521-3528)


1996 ◽  
Vol 271 (10) ◽  
pp. 5663-5670 ◽  
Author(s):  
Agnes Estival ◽  
Veronique Monzat ◽  
Karine Miquel ◽  
François Gaubert ◽  
Etienne Hollande ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document